Opening soon. Stay in the loop

goodmorrowJoin the opening list

GLP-1 Plus

Our program for what the medication doesn't fix on its own.

Updated Clinical review pending · Educational draft

What's in it

Why people combine them

GLP-1 medication is the most effective weight loss treatment most people will ever take. It also creates a few predictable problems. Some of the weight you lose is muscle. Visceral fat can lag behind the scale. Skin can loosen when weight comes off quickly. And nausea is common while the dose climbs.

The honest part

None of the add-ons below has been tested together with a GLP-1 in a large trial. Each one is here because it addresses a specific, measurable problem, and each one comes off the plan if it isn't helping.

How Goodmorrow does it

  • Muscle: a protein target and a strength plan from day one, checked at each visit. This matters more than any peptide.
  • Belly fat: tesamorelin, FDA-approved to reduce visceral fat, when your waist and labs say it's warranted.
  • Skin: topical GHK-Cu, and a plan for the loose skin that can come with fast weight loss.
  • Side effects: a slower dose schedule, food guidance and anti-nausea medication when you need it.
  • Metabolism: MOTS-c is on our watch list for when it becomes lawful.

What you can do today

Everything above except MOTS-c is available when we open. Your membership covers the care; tesamorelin and GHK-Cu are priced separately, and you'll see the price before you start.

Questions people ask

What should I take with Zepbound or Wegovy?

Start with protein and resistance training, because they protect muscle. Beyond that, it depends on your numbers. Tesamorelin for visceral fat and topical GHK-Cu for skin are the two add-ons we use most.

Do I need GLP-1 Plus to be a patient?

No. It's the same membership. The add-ons are optional and only appear on your plan if your clinician thinks they'll help.

Sources

  1. Research publicationTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine, 2022
  2. Research publicationOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021
  3. FDA documentEgrifta SV (tesamorelin) prescribing information U.S. Food and Drug Administration
  4. Research publicationRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data International Journal of Molecular Sciences, 2018

Good days ahead.

Join the opening list for appointment updates.

Join the opening list